{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:50:27Z","timestamp":1792018227670,"version":"4.4.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Getah virus (GetV) is an arthropod-borne alphavirus historically recognized as an emerging zoonotic pathogen of veterinary significance, particularly in livestock and equine populations across Asia and parts of the Western Pacific. Over the past several decades, its expanding ecological range, broad mosquito vector competence, and increasing frequency of animal outbreaks have positioned GetV as a growing concern for animal health surveillance, diagnostics, and vaccine development. However, beyond its established role in veterinary virology, a critical and underexplored dimension of GetV biology is its emerging potential in oncolytic virotherapy. Recent discoveries, particularly involving the M1 strain, reveal a striking capacity for tumor-selective replication driven by defects in antiviral innate immune signaling within malignant cells. This property positions GetV-derived platforms as promising candidates for next-generation oncolytic virus development, capable of direct tumor lysis and secondary activation of antitumor immunity. These findings signal a paradigm shift in how traditionally zoonotic alphaviruses may be repurposed for precision oncology. We therefore hypothesize that whilst broad cellular tropism enables Getah virus entry into different kinds of cells, the oncolytic efficacy requires another layer of intracellular permissiveness characterized by tumor-specific innate immune defects. This Perspective synthesizes the current state of knowledge on GetV from both veterinary and translational oncology viewpoints and outlines the dual-use trajectory of the virus from agricultural pathogen to therapeutic bioplatform. We further highlight unresolved questions surrounding mechanisms of tumor selectivity, biosafety and host restriction, genetic stability, immune modulation, and regulatory translational barriers. Addressing these gaps will be essential for advancing GetV-based oncolytic platforms toward clinical applicability. Collectively, GetV represents a compelling example of how emerging zoonotic viruses may be strategically repositioned at the interface of infectious disease surveillance and cancer therapy innovation.<\/jats:p>","DOI":"10.3389\/fcimb.2026.1768174","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:06:46Z","timestamp":1780466806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Can a mosquito-borne virus become a cancer therapy? rethinking Getah virus through the lens of oncolytic virotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Bernard B.","family":"Efa","sequence":"first","affiliation":[{"name":"Microbiology Program, Department of Biological Sciences, College of Science, Technology, Engineering and Mathematics, Alabama State University","place":["Montgomery, AL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Antwi-Osei Jnr","sequence":"additional","affiliation":[{"name":"Master of Public Health (MPH) Program, University of Delaware","place":["Newark, DE, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2020.271","article-title":"The identification and development of a novel oncolytic virus: Alphavirus M1","volume":"32","author":"Cai","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s12935-020-01598-w","article-title":"Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity","volume":"20","author":"Cai","year":"2020","journal-title":"Cancer Cell Int."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1308890","article-title":"Oncolytic virotherapy in cancer treatment: challenges and prospects","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1089\/vbz.2024.0100","article-title":"Isolation and characterization of Getah virus GD2202 from mosquitoes in Foshan, China","volume":"25","author":"Deng","year":"2025","journal-title":"Vector-Borne Zoonotic Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"108179","DOI":"10.1016\/j.pharmthera.2021.108103","article-title":"Oncolytic immunovirotherapy: crosstalk between oncolytic viruses and cancer immunology","volume":"236","author":"Feola","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/v14020327","article-title":"Structural insights into alphavirus assembly revealed by the cryo-EM structure of Getah virus","volume":"14","author":"Guo","year":"2022","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1583023","article-title":"First report on identification and genetic characterization of Getah virus in wild boar in China","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.coviro.2019.01.001","article-title":"Emergence and re-emergence of mosquito-borne arboviruses","volume":"34","author":"Huang","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.14202\/vetworld.2025.3464-3475","article-title":"Global seroprevalence and distribution of Getah virus in domestic and wild animals: a systematic review and meta-analysis","volume":"18","author":"Irekeola","year":"2025","journal-title":"Veterinary World"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s11538-018-0424-4","article-title":"Mathematical modelling of the interaction between cancer cells and an oncolytic virus: insights into the effects of treatment protocols","volume":"80","author":"Jenner","year":"2018","journal-title":"Bull. Math. Biol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33432","article-title":"Infectivity and pathogenesis characterization of Getah virus strain via different inoculation routes in mice","volume":"10","author":"Jian","year":"2024","journal-title":"Heliyon"},{"key":"B13","first-page":"2204.01238","article-title":"Mesenchymal stem cells as carrier cells to enable effective intratumoral delivery of oncolytic virus for oncolytic virotherapy: a systematic review","author":"Jittprasong","year":"2022","journal-title":"arXiv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ani14202980","article-title":"Novel porcine Getah virus from diarrheal piglets in Jiangxi Province, China: prevalence, genome sequence, and pathogenicity","volume":"14","author":"Lan","year":"2024","journal-title":"Animals"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11080945","article-title":"Getah virus (Alphavirus): an emerging, spreading zoonotic virus","volume":"11","author":"Li","year":"2022","journal-title":"Pathogens"},{"key":"B16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.meegid.2017.08.016","article-title":"From discovery to spread: the evolution and phylogeny of Getah virus","volume":"55","author":"Li","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal. Transduct Target Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"10849","DOI":"10.1073\/pnas.1408759111","article-title":"Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers","volume":"111","author":"Lin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0049-0","article-title":"M1 virus selectively targets ZAP-defective human cancers","volume":"7","author":"Meng","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent advances of oncolytic virus in cancer therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum. Vaccin Immunother."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.135274","article-title":"Getah virus Nsp3 binds G3BP to block formation of bona fide stress granules","volume":"279","author":"Qi","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2309.00821","DOI":"10.1016\/j.mbs.2023.109073","article-title":"On the treatment of melanoma: a mathematical model of oncolytic virotherapy","author":"Ramaj","year":"2023","journal-title":"arXiv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01091-22","article-title":"Early genomic surveillance and phylogeographic analysis of Getah virus in livestock in China","volume":"97","author":"Shen","year":"2025","journal-title":"J. Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1037","DOI":"10.1111\/tbed.14395","article-title":"Origin, genetic diversity, adaptive evolution, and transmission dynamics of Getah virus","volume":"69","author":"Shi","year":"2022","journal-title":"Transbound Emerg. Dis."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cells14221825","article-title":"A comprehensive review of modern cancer therapies utilizing oncolytic viruses","volume":"14","author":"Su\u0142ek","year":"2025","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/v14102173","article-title":"Seroprevalence of Getah virus in pigs in eastern China determined with a recombinant E2 protein-based indirect ELISA","volume":"14","author":"Sun","year":"2022","journal-title":"Viruses"},{"key":"B27","first-page":"1","article-title":"Getah virus fact sheet","year":"2021"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1292\/jvms.22-0306","article-title":"Seroconversion of anti-Getah virus antibody among Japanese native Noma horses around 2012","volume":"84","author":"Takeishi","year":"2022","journal-title":"J. Veterinary Med. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1093\/molbev\/msab120","article-title":"MEGA11: molecular evolutionary genetics analysis version 11","volume":"38","author":"Tamura","year":"2021","journal-title":"Mol. Biol. Evol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01751-21","article-title":"Attenuation of Getah virus by a single amino acid substitution at residue 253 of the E2 protein","volume":"96","author":"Wang","year":"2022","journal-title":"J. Virol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41421-022-00374-6","article-title":"Structure of infective Getah virus at 2.8 \u00c5 resolution determined by cryo-electron microscopy","volume":"8","author":"Wang","year":"2022","journal-title":"Cell. Discov."},{"key":"B32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.meegid.2017.08.016","article-title":"Evolution and phylogeny of Getah virus","volume":"55","author":"Yuan","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721830","article-title":"Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas","volume":"12","author":"Zeng","year":"2021","journal-title":"Front. Immunol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7996","article-title":"Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma","volume":"9","author":"Zhang","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01091-22","article-title":"Early genomic surveillance and phylogeographic analysis of Getah virus in China","volume":"97","author":"Zhao","year":"2023","journal-title":"J. Virol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1768174\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:06:47Z","timestamp":1780466807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1768174\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":35,"alternative-id":["10.3389\/fcimb.2026.1768174"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1768174","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1768174"}}